Medicinal Cannabis Access in Tasmania: A Regulatory Overview

Tasmania operates under two layers of law , and most people only know one of them

Forty-three. That's the number of pages in the current Poisons Standard that are directly relevant to cannabis scheduling in Australia. I've read them more times than I'd like to admit, usually with a strong flat white and the company of Trevor, my sourdough starter, bubbling away on the bench beside me. The point is: the federal framework is dense, and when you layer a state jurisdiction over the top of it, things get more layered still.

Tasmania is a useful case study precisely because it's small, geographically distinct, and has a historic relationship with licensed cannabis cultivation , for industrial hemp and, separately, pharmaceutical opioid poppy production , that colours how the state has approached the medicinal space. But none of that history changes the fundamental structure. Access to medicinal cannabis in Tasmania is governed first by federal law and, within that, by state-level scheduling and prescribing rules.

The federal foundation: scheduling and the Poisons Standard

Australia's Therapeutic Goods Administration (TGA) controls the scheduling of cannabis-derived substances under the Poisons Standard (formally the Standard for the Uniform Scheduling of Medicines and Poisons). The two schedules that matter most here are Schedule 4 (Prescription Only) and Schedule 8 (Controlled Drug).

Broadly speaking: cannabidiol (CBD) products containing low concentrations of CBD, formulated for specific use cases and meeting defined criteria, sit in Schedule 4. Products containing THC; or higher-concentration CBD products, generally sit in Schedule 8. Schedule 8 carries stricter prescribing, recording, and dispensing obligations. A product's placement in one schedule or the other has real downstream consequences for how a Tasmanian prescriber must handle it.

Products must also appear on the Australian Register of Therapeutic Goods (ARTG) or be accessed via one of two approved pathways: the Special Access Scheme (SAS) or the Authorised Prescriber (AP) scheme. These are federal mechanisms administered by the TGA. Tasmania's state rules operate within, not instead of; this system.

How Tasmania applies the scheduling overlay

Each state and territory in Australia adopts the Poisons Standard into its own legislation. In Tasmania, the relevant instrument is the Poisons Act 1971 and associated regulations. The Act gives effect to the national scheduling framework but adds Tasmanian-specific requirements around: which health practitioners may prescribe controlled substances, how Schedule 8 permits are granted, record-keeping at dispensing pharmacies, and the permit conditions that apply to Schedule 8 prescribing.

For Schedule 8 medicinal cannabis products, the majority of what patients in Tasmania will access, a prescribing doctor generally requires approval under both the federal SAS or AP pathway and a state-level Schedule 8 permit issued by the Tasmanian Department of Health. The permit requirement is not unique to cannabis; it applies across Schedule 8 substances. But it does mean an extra administrative step that some interstate prescribers occasionally overlook when they have Tasmanian patients.

I'd argue this dual-approval architecture is one of the more genuinely confusing aspects of the Australian system for patients and GPs alike. The federal TGA approval says "this substance can be prescribed." The state permit says "this prescriber in this jurisdiction is approved to prescribe it." Both gates have to be open before a patient can legally receive the product.

Access pathways in practice

The SAS Category B pathway is the most commonly used route for first-time prescribers. Under SAS Category B, a medical practitioner submits an application to the TGA for a specific, named patient before prescribing an unapproved therapeutic good; including most medicinal cannabis products. Approvals are typically processed within a few business days for straightforward applications, though timelines vary.

The Authorised Prescriber scheme suits practitioners who regularly prescribe to a defined patient population with a particular condition. An AP approval, once granted, allows ongoing prescribing without per-patient TGA applications. In Tasmania, as elsewhere, the AP must still hold the relevant state Schedule 8 permit for cannabis products.

There is also a small but meaningful number of ARTG-listed medicinal cannabis products, meaning they've been through full TGA registration. These can be prescribed by any registered medical practitioner, subject to the Schedule 8 permit requirements that apply in Tasmania. The ARTG-listed category remains limited in number compared to the much larger pool of SAS-accessed unapproved products.

The cultivation side: Tasmania's particular history

Tasmania has been licenced to cultivate Cannabis sativa for pharmaceutical purposes for decades, primarily for alkaloid extraction in the pharmaceutical poppy industry, which is separate from the medicinal cannabis supply chain. But that regulatory familiarity with controlled plant cultivation means the Office of Drug Control (ODC), the federal body that licences cannabis cultivation and manufacture under the Narcotic Drugs Act 1967, has dealt with Tasmanian licence holders for years.

Medicinal cannabis cultivation licences and manufacture licences issued under the Narcotic Drugs Act are federal instruments. A grower or manufacturer in Tasmania holds an ODC licence regardless of state location. The products they produce must meet Good Manufacturing Practice (GMP) standards; Australian GMP or an equivalent recognised standard, before they can enter the legal supply chain.

Understanding what's actually in those products requires engaging with some chemistry. Medicinal cannabis products vary considerably in their cannabinoid profiles: some are full-spectrum, containing the range of compounds present in the plant including minor cannabinoids and terpenes; others are broad-spectrum or isolate-based. The endocannabinoid system, the receptor network these compounds interact with; is covered separately in our glossary, but it's worth knowing that the scheduling of a product depends on its cannabinoid content, not its extraction method.

What GPs and nurse practitioners need to know

Nurse practitioners in Tasmania may prescribe Schedule 4 medicines within their scope of practice, but Schedule 8 prescribing authority for nurse practitioners varies and is subject to specific state authorisation. It's an area where the rules genuinely differ between jurisdictions, and it catches people out. My strong recommendation: verify current authorisation directly with the Tasmanian Department of Health rather than relying on information from another state's prescribing guidelines.

GPs wanting to prescribe medicinal cannabis in Tasmania for the first time should: confirm they hold (or apply for) the relevant Schedule 8 permit from the Tasmanian Department of Health; submit an SAS Category B application to the TGA for the specific patient and product; and satisfy themselves that the product they're considering is either ARTG-listed or being accessed via an approved SAS or AP pathway. The TGA's online SAS portal, accessible via tga.gov.au, handles the federal component.

Record-keeping under the Poisons Act 1971 (Tas) requires that Schedule 8 prescriptions and dispensing records be maintained in the form specified by the regulations. Pharmacists dispensing medicinal cannabis products need to be satisfied the prescription meets state requirements, including any permit number that may need to appear on the prescription face.

For patients: what the access pathway looks like

A patient in Hobart or Launceston, or anywhere else in Tasmania; cannot simply request a medicinal cannabis product and receive one. The prescribing doctor must have the relevant approvals in place, the product must be legally accessible via one of the approved pathways, and the dispensing pharmacy must be able to source and dispense it correctly.

That said, the number of approved prescribers and participating pharmacies has grown considerably since the SAS Category B process was streamlined around 2020–2021. The TGA's published data shows tens of thousands of SAS approvals issued nationally per year, and Tasmania, while a small state by population, reflects that broader trend. The friction is lower than it was five years ago. But "lower friction" is not the same as "straightforward," and patients should be prepared for the administrative steps involved.

Laws in this area change. The Poisons Standard is updated regularly, state regulations are amended, and TGA guidance evolves. The snapshot here reflects publicly available information as at mid-2025. Anyone making clinical or legal decisions should verify current requirements directly with the TGA (tga.gov.au) and the Tasmanian Department of Health.

Sources

• Medicinal Cannabis Hub, Therapeutic Goods Administration (TGA)
• Narcotic Drugs Act 1967 (Cth), Federal Register of Legislation
• Schedule 8 Poisons; Tasmanian Department of Health
• Guidance on the Use of Medicinal Cannabis in Australia: Overview, TGA

, Marcus Hale, Regulatory researcher, TGA & access law